糖心vlog

[Skip to Navigation]
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
糖心vlog Home
JAMA Oncology
Sign In
New Online Current Issue Past Issues
糖心vlog Statement on Potentially Offensive Content

October 2024 - April 2015

Decade

Year

Issue

November 2023, Vol 9, No. 11, Pages 1486-1592

Original Investigation

Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non鈥揝mall Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial

Motoko Tachihara, MD, PhD; Kayoko Tsujino, MD, PhD; Takeaki Ishihara, MD, PhD; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1505-1513. doi:10.1001/jamaoncol.2023.3309

This single-arm, phase 2 nonrandomized controlled trial assesses the efficacy and safety of durvalumab with concurrent radiotherapy followed by durvalumab for treatment of patients with unresectable, locally advanced non鈥搒mall cell lung cancer.

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer

Burcu F. Darst, PhD; Ed Saunders, MRes; Tokhir Dadaev, MSc; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1514-1524. doi:10.1001/jamaoncol.2023.3482

This genetic association study examines the association between variants of established prostate cancer risk genes and the risk of aggressive prostate cancer.

Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial

Michael F. Gensheimer, MD; Harriet Gee, MD, PhD; Hiroki Shirato, MD, PhD; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1525-1534. doi:10.1001/jamaoncol.2023.3495

This nonrandomized controlled trial of patients diagnosed with non鈥搒mall cell lung cancer assesses whether individualizing stereotactic ablative radiotherapy dose and fractionation by tumor size, location, and histological characteristics may be associated with local tumor control and the rate of toxic effects.

Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial

Marliese Alexander, PhD; Sam Harris, MBBS; Craig Underhill, MBBS; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1536-1545. doi:10.1001/jamaoncol.2023.3634

This randomized clinical trial evaluates whether a biomarker-driven, risk-directed approach to thromboprophylaxis would prevent thromboembolism among adults with lung and gastrointestinal (GI) cancers receiving anticancer therapies in ambulatory treatment settings.

Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial

Elizabeth M. Swisher, MD; Nadine Rayes, CGC; Deborah Bowen, PhD; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1547-1555. doi:10.1001/jamaoncol.2023.3748

This randomized clinical trial evaluates whether eliminating pretest and/or posttest counseling for home-delivered cancer risk assessment is noninferior with regard to participant distress.

Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial

Oreste Davide Gentilini, MD; Edoardo Botteri, PhD; Claudia Sangalli, BSc; et al.
Abstract Full Text
open access has audio
JAMA Oncol. 2023;9(11):1557-1564. doi:10.1001/jamaoncol.2023.3759

This randomized clinical trial assesses whether the omission of sentinel node biopsy is noninferior to sentinel lymph node biopsy in female patients with small breast cancer and negative results on preoperative ultrasonography of axillary lymph nodes.

  • Podcast: Sentinel Lymph Node Biopsy vs No Axillary Procedure in Small Node-Negative Breast Cancer

Radiotherapy Plus Cisplatin With or Without Lapatinib for Non鈥揌uman Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial

Stuart J. Wong, MD; Pedro A. Torres-Saavedra, PhD; Nabil F. Saba, MD; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1565-1573. doi:10.1001/jamaoncol.2023.3809

This randomized clinical trial examines whether lapatinib combined with a cisplatin-based combination radiation regimen is effective for the treatment of patients with locally advanced head and neck cancer with poor prognosis.

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

Tae Won Kim, MD; Philippe L. Bedard, MD; Patricia LoRusso, DO; et al.
Abstract Full Text
open access
JAMA Oncol. 2023;9(11):1574-1582. doi:10.1001/jamaoncol.2023.3867

This nonrandomized controlled trial evaluates the safety and antitumor activity of anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors.

Research Letter

Prevalence of Thromboembolic Events in Patients With Non鈥揝mall Cell Lung Cancer and RET Fusions

Mihaela Aldea, MD, PhD; Arianna Marinello, MD; David Guyon, MD; et al.
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1583-1584. doi:10.1001/jamaoncol.2023.3625

This cohort study examines the incidence, risks, and characteristics of deep vein thrombosis, pulmonary embolism, arterial thrombosis, and stroke among patients with non鈥搒mall cell lung cancer (NSCLC) and RET fusions.

Viewpoint

Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?

Austin Wesevich, MD, MPH; Mark J. Ratain, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1489-1490. doi:10.1001/jamaoncol.2023.3292

This Viewpoint discusses the US Food and Drug Administration鈥檚 Project Optimus, which focuses on new oncology drug dose optimization and examines concerns about the accelerated postmarketing approval of adjusted dosing of oncologic drugs.

Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer

Thomas J. Hwang, MD; Benjamin J. Davies, MD; Mark A. Preston, MD, MPH
Abstract Full Text
JAMA Oncol. 2023;9(11):1491-1492. doi:10.1001/jamaoncol.2023.3304

This Viewpoint encourages investigators to move beyond FDA guidance toward patient-centered therapies and health equity for BCG-unresponsive bladder cancer.

Medical Travel for Immigrant Patients With Cancer鈥擱eturning Home

Nishwant Swami, MD, MPH; Edward Christopher Dee, MD; Narjust Florez, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1493-1494. doi:10.1001/jamaoncol.2023.3508

This Viewpoint describes motivations for and barriers to travel to the country of origin among immigrant patients with cancer and recommends strategies to address these motivations and barriers.

Climate Change and Cancer Care鈥擣eeling the Heat

Joan H. Schiller, MD; Eric Bernicker, MD; Alexandra Thomas, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1495-1496. doi:10.1001/jamaoncol.2023.3511

This Viewpoint describes how climate change and air pollution markedly affect cancer incidence, care delivery, and patient outcomes.

Editorial

Rare Genetic Drivers of Lethal Prostate Cancer

Alexander W. Wyatt, BSc, DPhil
Abstract Full Text
JAMA Oncol. 2023;9(11):1499-1501. doi:10.1001/jamaoncol.2023.3352

Sentinel Node Biopsy for Early Breast Cancer鈥擜 SOUND for De-escalation

Seema A. Khan, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1501-1503. doi:10.1001/jamaoncol.2023.3667

Unlocking the Potential of Anti-TIGIT Therapy鈥擝etween Promise and Challenges

Joud Hajjar, MD, PhD, MS; Mohamed H. Derbala, MD; Aung Naing, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1503-1504. doi:10.1001/jamaoncol.2023.3835
Invited Commentary

Personalized Radiation Therapy鈥擲purning the 鈥淥ne Size Fits All鈥� Approach

Vivek Verma, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1534-1535. doi:10.1001/jamaoncol.2023.3350

Primary Thromboprophylaxis in People With Cancer鈥擶here Next?

Alok A. Khorana, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1545-1546. doi:10.1001/jamaoncol.2023.3569

Right-Sizing Models of Genetic Cancer Predisposition Testing

Huma Q. Rana, MD, MPH; Judy E. Garber, MD, MPH
Abstract Full Text
JAMA Oncol. 2023;9(11):1555-1556. doi:10.1001/jamaoncol.2023.3683
JAMA Oncology Patient Page

Geriatric Assessments in Older Adults With Cancer

Fernando C. Diaz, MD; Ana I. Velazquez, MD, MSc; Mazie Tsang, MD
Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1592. doi:10.1001/jamaoncol.2023.3329

This JAMA Oncology Patient Page describes the geriatric assessment used by clinicians to evaluate the health of older adults with cancer.

Cancer Care Chronicles

The Weight of Inevitability鈥擬y Journey With BRCA2

Katherine P. Wu, BA
Abstract Full Text
JAMA Oncol. 2023;9(11):1497-1498. doi:10.1001/jamaoncol.2023.3492

In this essay, the author grapples with the possibility of a diagnosis of BRCA2.

Poetry and Oncology

Stargazers

David Haosen Xiang, BA
Abstract Full Text
JAMA Oncol. 2023;9(11):1591. doi:10.1001/jamaoncol.2023.3326
Comment & Response

Ending One鈥檚 Life Is Not Always a Sign of Psychopathology

Douglas W. Heinrichs, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1584. doi:10.1001/jamaoncol.2023.2591

Ending One鈥檚 Life Is Not Always a Sign of Psychopathology鈥擱eply

Alexandra L. Potter, BS; Chinmay Haridas; Chi-Fu Jeffrey Yang, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1585. doi:10.1001/jamaoncol.2023.2594

Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen

Manuel David Gil-Sierra, PharmD; María del Pilar Briceño-Casado, PharmD; Cristina Moreno-Ramos, PharmD
Abstract Full Text
JAMA Oncol. 2023;9(11):1585-1586. doi:10.1001/jamaoncol.2023.3398

Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen鈥擱eply

Gaia Giannone, MD; Iain A. McNeish, MA, BMBCh, PhD; Susana Banerjee, MBBS, MA, PhD
Abstract Full Text
JAMA Oncol. 2023;9(11):1586-1587. doi:10.1001/jamaoncol.2023.3401

Metastases-Targeting Radiotherapy and ADT

Jui-Ming Liu, MD, PhD; Yung-Shuo Kao, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1587. doi:10.1001/jamaoncol.2023.3628

Metastases-Targeting Radiotherapy and ADT鈥擱eply

Alexander D. Sherry, MD; Paul G. Corn, MD, PhD; Chad Tang, MD
Abstract Full Text
JAMA Oncol. 2023;9(11):1587-1588. doi:10.1001/jamaoncol.2023.3631

Risk of Death Due to Pregnancy-Associated Cancers鈥擬ore Questions Than Answers

Jordyn Silverstein, MD; Katherine Van Loon, MD, MPH
Abstract Full Text
JAMA Oncol. 2023;9(11):1588-1589. doi:10.1001/jamaoncol.2023.3648

Risk of Death Due to Pregnancy-Associated Cancers鈥擬ore Questions Than Answers鈥擱eply

Zoe F. Cairncross, MPH; Gregg Nelson, MD; Amy Metcalfe, PhD
Abstract Full Text
JAMA Oncol. 2023;9(11):1589. doi:10.1001/jamaoncol.2023.3651
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2023;9(11):1486. doi:10.1001/jamaoncol.2022.4880
Most Viewed(30 Days) RSS link
Most Cited(3 Years) RSS Link
View more
View more
×
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)鈥�
Sign in or create a free account
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)鈥�
Sign in or create a free account
Sign in to access free PDF
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Save your search
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Make a comment
Free access to newly published articles
To register for email alerts, access free PDF, and more
Create a personal account or sign in to:
  • Register for email alerts with links to free full-text articles
  • Access PDFs of free articles
  • Manage your interests
  • Save searches and receive search alerts
Privacy Policy